|
|
 |
|
Viewing report
|
|
|
|
Amgen Inc.: PharmaVitae Profile
Datamonitor, June 2010, Pages: 105
Introduction
This analysis examines the historical and forecast performance for Amgen in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Amgen's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Amgen over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Amgen's performance against key rivals in the prescription pharmaceutical sector
- Analyze Amgen's diversification strategy which will be heavily reliant on the launch of the cross-therapy area monoclonal antibody Prolia/Xgeva
- Assess how Amgen's commercial performance out to 2015 will be impacted by the safety concerns relating to the ESA product class
|
|
|
|
